What is Abaloparatide?

A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.

Open the Abaloparatide reconstitution calculator

Abaloparatide in the library · Healing & Repair Peptides · Human Trials · What are peptides?

19 registered trials · 37 indexed papers · 151 human / 74 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Abaloparatide is described as a synthetic analog of parathyroid hormone-related peptide (PTHrP). It activates the PTH1 receptor to stimulate bone formation; in osteoporosis care, “anabolic” means bone-building rather than primarily slowing bone breakdown.

Registered human trials (19)

TrialPhaseStatusYearEnrolled
The Effect of Osteoporotic Medications on Vertebral Bone Quality ScorePhase 2enrolling by invitation202660
Supracondylar Distal Femur Fractures and AbaloparatidePhase 4withdrawn2024
Sequential Therapies After Osteoanabolic Treatmentrecruiting2023150
PTH Analog Type II Odontoid FracturePhase 2terminated202222
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AlonePhase 4active not recruiting202170
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Womencompleted202122054
Effect of Abaloparatide on Lumbar Disc DegenerationPhase 2withdrawn2021
Abaloparatide Before Total Knee ArthroplastyPhase 4completed202058
Abaloparatide and Pelvic Fracture HealingPhase 2completed202048
Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.Phase 1completed202052
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.Phase 1completed202036
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion SurgeryPhase 2active not recruiting201996
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)Phase 1completed201922
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With OsteoporosisPhase 3completed2019511
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesPhase 1completed201920
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)Phase 3completed2018228
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and ResorptionPhase 3completed201823
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With OsteoporosisPhase 2completed2012250
Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal WomenPhase 3completed20112463

Peer-reviewed studies (37)

PaperAuthorsJournalYearType
The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosisDeal C et al.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry2026Randomized Controlled Trial
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatideCosman F et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025Randomized Controlled Trial
Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) studyEastell R et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025Randomized Controlled Trial
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective AnalysisTabatabai L et al.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2025Observational Study
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)Wen MT et al.Expert opinion on drug safety2025Observational Study
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with OsteoporosisSheth NP et al.The Journal of bone and joint surgery. American volume2024Randomized Controlled Trial
Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational studyGold DT et al.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2024Observational Study
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trialSone T et al.Archives of osteoporosis2023Randomized Controlled Trial
Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 studyMatsumoto T et al.Journal of bone and mineral metabolism2023Randomized Controlled Trial
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized StudyLewiecki EM et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023Randomized Controlled Trial
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtendCosman F et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023Randomized Controlled Trial
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical TrialCzerwinski E et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2022Randomized Controlled Trial
Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J StudyMatsumoto T et al.The Journal of clinical endocrinology and metabolism2022Randomized Controlled Trial
Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal OsteoporosisWinzenrieth R et al.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry2022Clinical Trial
Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral DensityMiller PD et al.Clinical drug investigation2021Clinical Trial, Phase I
Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With OsteoporosisDempster DW et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2021Clinical Trial, Phase III
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 TrialCosman F et al.The Journal of clinical endocrinology and metabolism2020Randomized Controlled Trial
Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for FractureSaag KG et al.Clinical therapeutics2020Randomized Controlled Trial
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With OsteoporosisLeder BZ et al.The Journal of clinical endocrinology and metabolism2020Randomized Controlled Trial
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialBilezikian JP et al.Current medical research and opinion2019Randomized Controlled Trial
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend TrialLeder BZ et al.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2019Randomized Controlled Trial
Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosisWatts NB et al.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019Randomized Controlled Trial
Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probabilityMcCloskey EV et al.Archives of osteoporosis2019Randomized Controlled Trial
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVEEastell R et al.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019Randomized Controlled Trial
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trialMiller PD et al.Bone2019Randomized Controlled Trial
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with TeriparatideReginster JY et al.Calcified tissue international2018Randomized Controlled Trial
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisBone HG et al.The Journal of clinical endocrinology and metabolism2018Randomized Controlled Trial
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosisMcClung MR et al.Menopause (New York, N.Y.)2018Randomized Controlled Trial
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with AbaloparatideMcClung MR et al.Calcified tissue international2018Randomized Controlled Trial
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosisReginster JY et al.Expert opinion on pharmacotherapy2018Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Abaloparatide?

A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.

How many registered human trials study Abaloparatide?

The PeptideWhiz trial index lists 19 registered trials for Abaloparatide, the most recent from 2026.

How much published research exists on Abaloparatide?

The PeptideWhiz paper index links 37 PubMed papers to Abaloparatide; by study type, 151 human and 74 animal studies.

Which conditions is Abaloparatide researched for?

Osteoporosis and bone density.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research